Entera Bio Ltd.

NASDAQ
ENTX
paper.types.company
Rentabilité sur six mois: -23.46%
Rendement en dividendes: 0%
Secteur: Healthcare

Calendrier des promotions Entera Bio Ltd.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Entera Bio Ltd.

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures.

plus de détails
Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2018-06-28
ISIN
IL0011429839
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 453.47 1
P/BV 10.16 1
P/E 2144.95 1
Efficacité
Nom Signification Grade
ROA -90.2 0
ROE -103.34 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0285 10
Debt/Ratio 0.029 10
Debt/Equity 0.0337 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % -50.41 0
Rentabilité Ebitda, % -14.06 0
Rentabilité EPS, % -53.25 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 1.86 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 2.1 $ 1.86 $ 2.1 $ -11.43 % 0 % 0 %
common.calendar.number_days.30d 1.95 $ 1.82 $ 2.13 $ -4.62 % 0 % 0 %
common.calendar.number_days.90d 1.69 $ 1.6 $ 2.4 $ 10.06 % 0 % 0 %
common.calendar.number_days.180d 2.43 $ 1.6 $ 2.72 $ -23.46 % 0 % 0 %
common.calendar.number_days.1y 1.65 $ 1.48 $ 2.72 $ 12.52 % 0 % 0 %
common.calendar.number_days.3y 1.41 $ 0.5 $ 2.98 $ 31.91 % 0 % 0 %
common.calendar.number_days.5y 1.75 $ 0.5 $ 6.9 $ 6.29 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.5 $ 6.9 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 2.43 $ 1.6 $ 2.72 $ -23.46 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Ms. Miranda J. Toledano M.B.A. CEO & Director 418k 1977 (48 années)
Dr. Hillel Galitzer M.B.A., Ph.D. Chief Operating Officer 296k 1978 (47 années)
Ms. Dana Yaacov-Garbeli CPA Chief Financial Officer 193k 1983 (42 année)
Dr. Gregory Burshtein Ph.D. Chief of Research & Development 1976 (49 années)

Informations sur l'entreprise

Adresse: Israel, Jerusalem, Kiryat Hadassah Minrav Building - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.enterabio.com